{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:12:33Z","timestamp":1790626353780,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.leukres.2017.08.010","type":"journal-article","created":{"date-parts":[[2017,8,31]],"date-time":"2017-08-31T23:46:56Z","timestamp":1504223216000},"page":"89-95","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["A phase 1 study of the Janus kinase 2 (JAK2)V617F inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia"],"prefix":"10.1016","volume":"61","author":[{"given":"Srdan","family":"Verstovsek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben A.","family":"Mesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed E.","family":"Salama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Pitou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio P.","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory L.","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Giles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah N.","family":"D\u2019Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Walgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef T.","family":"Prchal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.leukres.2017.08.010_bib0005","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/sj.leu.2404955","article-title":"Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2017.08.010_bib0010","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3109\/10428194.2012.710905","article-title":"The evolving treatment paradigm in myelofibrosis","volume":"54","author":"Mesa","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2017.08.010_bib0015","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/cncr.22365","article-title":"The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients","volume":"109","author":"Mesa","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2017.08.010_bib0020","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1056\/NEJM200004273421706","article-title":"Myelofibrosis with myeloid metaplasia","volume":"342","author":"Tefferi","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2017.08.010_bib0025","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2017.08.010_bib0030","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A uniqueclonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"issue":"17","key":"10.1016\/j.leukres.2017.08.010_bib0035","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2017.08.010_bib0040","series-title":"SEER Cancer Statistics Review, 1975\u20132005","year":"2007"},{"issue":"1","key":"10.1016\/j.leukres.2017.08.010_bib0045","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2008-01-134858","article-title":"Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001\u20132004, using data from the NAACCR and SEER programs","volume":"112","author":"Rollison","year":"2008","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.leukres.2017.08.010_bib0050","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2006-12-064287","article-title":"Clinical profile of homozygous JAK2 617VF mutation in patients with polycythemia vera or essential thrombocythemia","volume":"110","author":"Vannucchi","year":"2007","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.leukres.2017.08.010_bib0055","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1182\/blood-2007-07-099184","article-title":"Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Italian Registry of Myelofibrosis. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis","volume":"110","author":"Barosi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.08.010_bib0060","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","article-title":"Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms","volume":"115","author":"Quintas-Cardama","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.08.010_bib0065","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ccr.2009.10.015","article-title":"The JAK2 inhibitor, AZD1480, potently blocks STAT3 signaling and oncogenesis in solid tumors","volume":"16","author":"Hedvat","year":"2009","journal-title":"Cancer Cell."},{"key":"10.1016\/j.leukres.2017.08.010_bib0070","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.leukres.2014.11.018","article-title":"A phase I, open-label, multi-center study of the JAK2 inhibitor AZD1480 in patients with myelofibrosis","volume":"39","author":"Verstovsek","year":"2015","journal-title":"Leuk. Res."},{"issue":"6","key":"10.1016\/j.leukres.2017.08.010_bib0075","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1517\/13543784.2013.774373","article-title":"Investigational janus kinase inhibitors","volume":"22","author":"Tam","year":"2013","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.leukres.2017.08.010_bib0080","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2017.08.010_bib0085","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2017.08.010_bib0090","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.leukres.2017.08.010_bib0095","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1055\/s-0038-1646373","article-title":"Protein S and C4b-binding protein: components involved in the regulation of the protein C anticoagulant system","volume":"66","author":"Dahlb\u00e4ck","year":"1991","journal-title":"Thromb. Haemost."},{"issue":"5","key":"10.1016\/j.leukres.2017.08.010_bib0100","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.4049\/jimmunol.169.5.2580","article-title":"Vitamin K-dependent protein S localizing complement regulator C4b-binding protein to the surface of apoptotic cells","volume":"169","author":"Webb","year":"2002","journal-title":"J. Immunol."},{"issue":"27","key":"10.1016\/j.leukres.2017.08.010_bib0105","doi-asserted-by":"crossref","first-page":"16074","DOI":"10.1016\/S0021-9258(17)46190-4","article-title":"Assembly of protein S and C4b-binding protein on membranes","volume":"265","author":"Schwalbe","year":"1990","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.leukres.2017.08.010_bib0110","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1055\/s-0031-1276584","article-title":"C4b-Binding protein: a forgotten factor in thrombosis and hemostasis","volume":"37","author":"Dahlback","year":"2011","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.leukres.2017.08.010_bib0115","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1038\/bcj.2013.6","article-title":"Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F","volume":"3","author":"Ma","year":"2013","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2017.08.010_bib0120","first-page":"40","volume":"vol. 2","author":"Swerdlow","year":"2008"},{"key":"10.1016\/j.leukres.2017.08.010_bib0125","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2004.05094.x","article-title":"Tumour lysis syndrome: new therapeutic strategies and classification","volume":"127","author":"Cairo","year":"2004","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.leukres.2017.08.010_bib0130","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/j.1365-2141.2010.08143.x","article-title":"TLS Expert Panel. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus","volume":"149","author":"Cairo","year":"2010","journal-title":"Br. J. Haematol."},{"issue":"9","key":"10.1016\/j.leukres.2017.08.010_bib0135","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.leukres.2009.01.035","article-title":"The myelofibrosis symptom assessment form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis","volume":"33","author":"Mesa","year":"2009","journal-title":"Leuk. Res."},{"issue":"5","key":"10.1016\/j.leukres.2017.08.010_bib0140","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J. Natl. Cancer Inst."},{"issue":"5","key":"10.1016\/j.leukres.2017.08.010_bib0145","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1182\/blood-2006-03-009746","article-title":"International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)","volume":"108","author":"Tefferi","year":"2006","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.leukres.2017.08.010_bib0150","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1182\/blood-2008-09-176818","article-title":"Response criteria for essential thrombocythemia and polycythemia vera; result of a European LeukemiaNet consensus conference","volume":"113","author":"Barosi","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.08.010_bib0155","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.leukres.2013.12.006","article-title":"Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor","volume":"38","author":"Verstovsek","year":"2014","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2017.08.010_bib0160","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1200\/JCO.2010.32.8021","article-title":"Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis","volume":"29","author":"Pardanani","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.leukres.2017.08.010_bib0165","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1124\/dmd.114.060673","article-title":"Impact on creatinine renal clearance by the interplay of multiple renal transporters: a case study with INCB039110","volume":"43","author":"Zhang","year":"2015","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.leukres.2017.08.010_bib0170","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.neuron.2011.11.024","article-title":"The JAK\/STAT pathway is involved in synaptic plasticity","volume":"73","author":"Nicolas","year":"2012","journal-title":"Neuron"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212617304915?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212617304915?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T08:08:26Z","timestamp":1620979706000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212617304915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":34,"alternative-id":["S0145212617304915"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2017.08.010","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.731255028.793541439","asserted-by":"object"}]},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase 1 study of the Janus kinase 2 (JAK2)V617F inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2017.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}